Karwacka M, Olejniczak M
Cells. 2022; 11(3).
PMID: 35159326
PMC: 8834129.
DOI: 10.3390/cells11030517.
Dufour B, McBride J
Exp Neurol. 2016; 283(Pt A):308-17.
PMID: 27381424
PMC: 4992622.
DOI: 10.1016/j.expneurol.2016.06.028.
Bayram-Weston Z, Jones L, Dunnett S, Brooks S
PLoS One. 2016; 11(5):e0155834.
PMID: 27196694
PMC: 4873140.
DOI: 10.1371/journal.pone.0155834.
Wear M, Kryndushkin D, OMeally R, Sonnenberg J, Cole R, Shewmaker F
PLoS One. 2015; 10(8):e0136362.
PMID: 26317359
PMC: 4552826.
DOI: 10.1371/journal.pone.0136362.
Rub U, Hentschel M, Stratmann K, Brunt E, Heinsen H, Seidel K
Brain Pathol. 2014; 24(3):247-60.
PMID: 24779419
PMC: 4160739.
DOI: 10.1111/bpa.12115.
Intrajugular vein delivery of AAV9-RNAi prevents neuropathological changes and weight loss in Huntington's disease mice.
Dufour B, Smith C, Clark R, Walker T, McBride J
Mol Ther. 2014; 22(4):797-810.
PMID: 24390280
PMC: 3982495.
DOI: 10.1038/mt.2013.289.
A novel BACHD transgenic rat exhibits characteristic neuropathological features of Huntington disease.
Yu-Taeger L, Petrasch-Parwez E, Osmand A, Redensek A, Metzger S, Clemens L
J Neurosci. 2012; 32(44):15426-38.
PMID: 23115180
PMC: 6621569.
DOI: 10.1523/JNEUROSCI.1148-12.2012.
Protein misfolding detected early in pathogenesis of transgenic mouse model of Huntington disease using amyloid seeding assay.
Gupta S, Jie S, Colby D
J Biol Chem. 2011; 287(13):9982-9989.
PMID: 22187438
PMC: 3323021.
DOI: 10.1074/jbc.M111.305417.
Huntington's disease: can mice lead the way to treatment?.
Crook Z, Housman D
Neuron. 2011; 69(3):423-35.
PMID: 21315254
PMC: 4685469.
DOI: 10.1016/j.neuron.2010.12.035.
Neuroanatomic profile of polyglutamine immunoreactivity in Huntington disease brains.
Herndon E, Hladik C, Shang P, Burns D, Raisanen J, White 3rd C
J Neuropathol Exp Neurol. 2009; 68(3):250-61.
PMID: 19225411
PMC: 2756075.
DOI: 10.1097/NEN.0b013e318198d320.
Huntington disease models and human neuropathology: similarities and differences.
Vonsattel J
Acta Neuropathol. 2007; 115(1):55-69.
PMID: 17978822
PMC: 2847401.
DOI: 10.1007/s00401-007-0306-6.
Neuronal intranuclear and neuropil inclusions for pathological assessment of Huntington's disease.
Maat-Schieman M, Roos R, Losekoot M, Dorsman J, Welling-Graafland C, Hegeman-Kleinn I
Brain Pathol. 2007; 17(1):31-7.
PMID: 17493035
PMC: 8095615.
DOI: 10.1111/j.1750-3639.2006.00040.x.
Characterization of intracellular aggregates using fluorescently-tagged polyglutamine-expanded androgen receptor.
Panet-Raymond V, GOTTLIEB B, Beitel L, Schipper H, Timiansky M, Pinsky L
Neurotox Res. 2004; 3(3):259-75.
PMID: 15111251
DOI: 10.1007/BF03033265.
Calmodulin regulates transglutaminase 2 cross-linking of huntingtin.
Zainelli G, Ross C, Troncoso J, Fitzgerald J, Muma N
J Neurosci. 2004; 24(8):1954-61.
PMID: 14985437
PMC: 6730388.
DOI: 10.1523/JNEUROSCI.4424-03.2004.
Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease.
Turmaine M, Raza A, Mahal A, Mangiarini L, Bates G, Davies S
Proc Natl Acad Sci U S A. 2000; 97(14):8093-7.
PMID: 10869421
PMC: 16675.
DOI: 10.1073/pnas.110078997.
Evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease in cell culture and in transgenic mice expressing mutant huntingtin.
Hackam A, Hodgson J, Singaraja R, Zhang T, Gan L, Gutekunst C
Philos Trans R Soc Lond B Biol Sci. 1999; 354(1386):1047-55.
PMID: 10434304
PMC: 1692613.
DOI: 10.1098/rstb.1999.0457.
From neuronal inclusions to neurodegeneration: neuropathological investigation of a transgenic mouse model of Huntington's disease.
Davies S, Turmaine M, Cozens B, Raza A, Mahal A, Mangiarini L
Philos Trans R Soc Lond B Biol Sci. 1999; 354(1386):971-9.
PMID: 10434295
PMC: 1692612.
DOI: 10.1098/rstb.1999.0448.